China’s Innovent Biologics signs US$10.5 billion Pfizer deal for 12 cancer drug trials
Innovent Biologics, a Chinese biopharmaceutical company, has entered into a significant partnership with Pfizer. The deal, valued at $10.5 billion, will focus on the development of 12 cancer drug trials. This collaboration aims to enhance cancer treatment options and expand both companies' portfolios in oncology.
- ▪Innovent Biologics has signed a $10.5 billion deal with Pfizer.
- ▪The partnership will involve 12 cancer drug trials.
- ▪This collaboration is expected to improve cancer treatment options.
Opening excerpt (first ~120 words) tap to expand
.css-1e339y7{z-index:1400;}.css-1e339y7 .MuiDrawer-paper{overflow-y:hidden;}.css-1e339y7 .MuiDrawer-modal{background:rgba(0, 0, 0, 0.2);}.css-1h2k762{z-index:1200;z-index:1400;}.css-1h2k762 .MuiDrawer-paper{overflow-y:hidden;}.css-1h2k762 .MuiDrawer-modal{background:rgba(0, 0, 0, 0.2);}.css-1whztno{position:relative;}.css-1whztno:first-of-type .er6t7fe40>*:first-child{padding-block-start:0;}.css-ahnbry>*:first-child{padding-block:var(--mobile-widget-gap, 16px);}@media (min-width:768px){.css-ahnbry>*:first-child{padding-block:40px;}}.css-hhdj32{--content-tablet-up-max-inline-size:600px;--widget-extra-padding:12px;--mobile-widget-gap:16px;--desktop-widget-gap:18px;display:grid;grid:"header-container" min-content "leading" min-content "content-container" min-content "widgets-bottom"…
Excerpt limited to ~120 words for fair-use compliance. The full article is at South China Morning Post.